News & Updates

Show Multimedia Only

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

07 Jul 2023

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

07 Jul 2023

More evidence for COVID-19 vaccine safety in kids

05 Jul 2023

COVID-19 vaccines can be safely administered in children, with a recent study showing that out of the numerous health outcomes monitored in near real time, the safety signal identified was for only myocarditis or pericarditis.

05 Jul 2023

COVID outcomes worse in polluted cities

01 Jul 2023 by

More evidence suggests that people exposed to more air pollution during the pandemic are at greater risk for COVID-19 infection, hospitalization, and death, but the exact mechanism behind the link is unknown.

01 Jul 2023

New scorecard helps detect peanut allergy

27 Jun 2023 by

Paediatricians may have a new tool in a scorecard that could ably detect peanut allergy in infants with atopic dermatitis (AD).

27 Jun 2023

Dolutegravir safe, effective in paediatric HIV

24 Jun 2023

Use of dolutegravir (DTG) proves to be effective and safe in children and adolescents living with HIV (CALHIV) in low- and middle-income countries (LMICs), as shown in a study.

24 Jun 2023

Neutrophilia, leukocytosis tied to poor outcomes in paediatric liver abscess

23 Jun 2023

In children with liver abscess, factors such as age-related leukocytosis, neutrophilia, elevated aspartate transaminase or alanine transaminase, and hypoalbuminaemia at presentation are significantly associated with poor outcomes, suggests a study.

23 Jun 2023

GBDT model predicts IVIG-resistant Kawasaki disease

22 Jun 2023

The gradient boosting decision tree (GBDT) model appears more reliable than previous models in predicting intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD), reports a study.

22 Jun 2023

Gliosis may explain depressive or cognitive symptoms after COVID

22 Jun 2023 by

Patients with persistent depressive or cognitive symptoms after an acute SARS-CoV-2 infection have elevated gliosis – a secondary event to brain injury – and inflammation as shown in a case-control study.

22 Jun 2023

COVID-19 oral antivirals reduce hospitalization and inpatient progression in nursing home residents

21 Jun 2023 by

A territory-wide, retrospective cohort study in Hong Kong has shown that molnupiravir and nirmatrelvir/ritonavir are effective in reducing the risks of hospitalization and inpatient disease progression among older patients residing in nursing homes.

21 Jun 2023

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?

17 Jun 2023

Critically ill patients with sepsis or septic shock who use ursodeoxycholic acid (UDCA) do not seem to experience improvement in shock severity and resolution, reveals a recent study. However, they have a higher chance of being extubated and not needing mechanical ventilation (MV) on the third day of admission to the intensive care unit (ICU).

17 Jun 2023

News & Updates

Showing Infectious Diseases articles

Showing

Specialty:

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

More evidence for COVID-19 vaccine safety in kids

COVID outcomes worse in polluted cities

New scorecard helps detect peanut allergy

Dolutegravir safe, effective in paediatric HIV

Neutrophilia, leukocytosis tied to poor outcomes in paediatric liver abscess

GBDT model predicts IVIG-resistant Kawasaki disease

Gliosis may explain depressive or cognitive symptoms after COVID

COVID-19 oral antivirals reduce hospitalization and inpatient progression in nursing home residents

Is ursodeoxycholic acid beneficial in critically ill patients with sepsis?